• Novartis exercises rights to Ionis’ CV drug TQJ230 pharmaceutical-technology
    February 26, 2019
    Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy....
PharmaSources Customer Service